Sponsored Links
| Angiotech Pharmaceuticals And Partner Athersys Announce Positive Results From Phase I Study Of MultiStem(R) In Heart Attack Patients |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) announced positive results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack... Read more: Pharma Industry / Biotech Industry News From Medical News Today
|